Inhibition of microtubule polymerization by 3-bromopropionylamino benzoylurea (JIMB01), a new cancericidal tubulin ligand

Biochemical Pharmacology

Volumn 65, Issue 10, 2003, Pages 1691-1699

  Li, Jian Nong ^a   Song, Dan Qing ^a   Lin, Yi He ^b   Hu, Qiong Ying ^a   Yin, Lu ^a   Bekesi, George ^c   Holland, James F ^c   Jiang, Jian Dong ^a,c  

^a INSTITUTE OF MEDICINAL BIOTECHNOLOGY   (China)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Antimicrotubule; Apoptosis; Chemotherapy; Hepatocarcinoma; JIMB01

Indexed keywords

3 BROMOPROPIONYLAMINOBENZOYLUREA; ANTINEOPLASTIC AGENT; CYCLIN B1; JIMB 01; PROTEIN BCL 2; UNCLASSIFIED DRUG; VINCRISTINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BODY WEIGHT; CELL CYCLE G2 PHASE; CONTROLLED STUDY; DNA DEGRADATION; DRUG BIOAVAILABILITY; DRUG EFFECT; DRUG MECHANISM; ENZYME ACTIVITY; FLOW CYTOMETRY; GEL ELECTROPHORESIS; HUMAN; HUMAN CELL; LD 50; LIVER CELL CARCINOMA; MALE; METAPHASE; MICROTUBULE ASSEMBLY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; TUMOR VOLUME; WESTERN BLOTTING;

EID: 0038392840     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(03)00101-1     Document Type: Article

References (37)

1. Rowinsky E.K., Donehower R.C. The clinical pharmacology and use of antimicrotubule agents in cancer chemotherapeutics. Pharmacol. Ther. 52:1991;35-84.
2. Malawista S.E., Bensch K.G., Sato H. Vinblastine and griseofulvin reversibly disrupt the living mitotic spindle. Science. 160:1968;770-772.
3. Wilson L. Properties of colchicine binding protein from chick embryo brain. Interactions with vinca alkaloids and podophyllotoxin. Biochemistry. 9:1970;4999-5007.
4. Dumontet C., Sikic B. Mechanisms of action of and resistance to anti-tubulin agents: microtubule dynamics, drug transport and cell death. J. Clin. Oncol. 17:1999;1061-1070.
5. Schiff P.B., Fant J., Horwitz S.B. Promotion of microtubule assembly in vitro by taxol. Nature. 277:1979;665-667.
6. Schiff P.B., Horwitz S.B. Taxol stabilizes microtubules in mouse fibroblast cells. Proc. Natl. Acad. Sci. U.S.A. 77:1980;1561-1565.
7. Sandercock J., Parmar M.K., Torri V. First-line chemotherapy for advanced ovarian cancer: paclitaxel, cisplatin and the evidence. Br. J. Cancer. 78:1998;1471-1478.
8. Miller K.D., Sledge G.W. Jr. Taxanes in the treatment of breast cancer: a prodigy comes of age. Cancer Invest. 17:1999;121-136.
9. Huang Y., Ibrado A.M., Reed J.C., Bullock G., Ray S., Tang C., Bhalla K. Co-expression of several molecular mechanisms of multidrug resistance and their significance for paclitaxel cytotoxicity in human AML HL-60 cells. Leukemia. 11:1997;253-257.
10. Dey S., Ramachandra M., Pastan I., Gottesman M.M., Ambudkar S.V. Evidence for two nonidentical drug-interaction sites in the human P-glycoprotein. Proc. Natl. Acad. Sci. U.S.A. 94:1997;10594-10599.
11. Jiang J.D., Davis A.S., Middleton K., Ling Y.H., Perez-Soler R., Holland J.F., Bekesi J.G. 3-(Iodoacetamido)-benzoylurea: a novel cancericidal tubulin ligand that inhibits microtubule polymerization, phosphorylates bcl-2, and induces apoptosis in tumor cells. Cancer Res. 58:1998;5389-5395.
12. Wu-Wong J.R., Alder J.D., Alder L., Burns D.J., Han E.K., Credo B., Tahir S.K., Dayton B.D., Ewing P.J., Chiou W.J. Identification and characterization of A-105972, an antineoplastic agent. Cancer Res. 61:2001;1486-1492.
13. Beckers T., Reissmann T., Schmidt M., Burger A.M., Fiebig H.H., Vanhoefer U., Pongratz H., Hufsky H., Hockemever J., Frieser M., Mahboobi S. 2-Aroylindoles, a novel class of potent, orally active small molecule tubulin inhibitors. Cancer Res. 62:2002;3113-3119.
14. Schlesinger M., Jiang J.D., Roboz J.P., Denner L., Ling Y.H., Holland J.F., Bekesi G.J. 3-m-Bromoacetylamino benzoic acid ethyl ester: a new cancericidal agent that activates the apoptotic pathway through caspase-9. Biochem. Pharmacol. 60:2000;1693-1702.
15. Rubinstein L.V., Shoemaker R.H., Paull K.D., Simon R.M., Tosini S., Skehan P., Scudiero D.A., Monks A., Boyd M.R. Comparison of in vitro anticancer-drug-screening data generated with a tetrazolium assay versus a protein assay against a diverse panel of human tumor cell lines. J. Natl. Cancer Inst. 82:1990;1113-1118.
16. Roboz J., Jiang J., Holland J.F., Bekesi J.G. Selective tumor apoptosis by MF13, L-prolyl-L-m-[bis(chloroethyl)amino]-phenylalanyl-L-norvaline ethyl ester, a new sarcolysin containing tripeptide. Cancer Res. 57:1997;4795-4802.
17. WAF1 and p53 requires c-raf-1. Cancer Res. 55:1995;4623-4626.
18. Shi Y., Glynn J.M., Guilbert L.J., Cotter T.G., Bissonnette R.P., Green D.R. Role for c-myc in activation-induced apoptotic cell death in T-cell hybridomas. Science. 257:1992;212-214.
19. Dolan M.E., Fleig M.J., Feuerstein B.G., Basu H.S., Luk G.D., Casero R.A. Jr., Marton L.J. Effect of 1,19-bis(ethylamino)-5,10,15-triazanonadecane on human tumor xenografts. Cancer Res. 54:1994;4698-4702.
20. Yagi M.J., Bekesi J.G. Evaluation of p-F-Phe-m-bis-(2-chloroethyl) amino-L-Phe-Met-ethoxy HCl against transplantable and spontaneous murine neoplasia. Cancer Chemother. Pharmacol. 26:1990;215-220.
21. Blagosklonny M.V., Giannakakou P., el-Deiry W.S., Kingston D.G., Higgs P.I., Neckers L., Fojo T. Raf-1/bcl-2 phosphorylation: a step from microtubule damage to cell death. Cancer Res. 57:1997;130-135.
22. Halder S., Basu A., Croce C.M. Bcl-2 is the guardian of microtubule integrity. Cancer Res. 57:1997;229-233.
23. Ogawa T., Mimura Y., Isowa K., Kato H., Mitsuishi M., Toyoshi T., Kuwayama N., Morimoto H., Murakoshi M., Nakayama T. An antimicrotubule agent, TZT-1027, does not induce neuropathologic alterations which are detected after administration of vincristine or paclitaxel in animal models. Toxicol. Lett. 121:2001;97-106.
24. Wilson L., Jordan M.A. Microtubule dynamics: taking aim at a moving target. Chem. Biol. 2:1995;569-573.
25. Hyams JS, Lloyd CW. Microtubules. New York: Wiley-Liss; 1994.
26. Jordan M.A., Wilson L. Microtubules and actin filaments: dynamic targets for cancer chemotherapy. Curr. Opin. Cell Biol. 10:1998;123-130.
27. Hood K.A., West L.M., Rouwe B., Northcote P.T., Berridge M.V., Wakefield S.J., Miller J.H. Peloruside A, a novel antimitotic agent with paclitaxel-like microtubule stabilizing activity. Cancer Res. 62:2002;3356-3360.
28. Fabre C., Czaplicki J., Wright M., Hill B., Barret J.M., Fahy J., Milon A. Differential binding to the α/β-tubulin dimer of vinorelbine and vinflunine revealed by nuclear magnetic resonance analyses. Biochem. Pharmacol. 64:2002;733-742.
29. Haldar S., Chintapalli J., Croce C.M. Taxol induced bcl-2 phosphorylation and death of prostate cancer cells. Cancer Res. 56:1996;1253-1255.
30. Halder S., Jena N., Crice C.M. Inactivation of bcl-2 by phosphorylation. Proc. Natl. Acad Sci. U.S.A. 92:1995;4507-4511.
31. Alberts B, Bray D, Lewis J, Raff M, Roberts K, Watson JD, editors. The cytoskeleton. In: Molecular biology of the cell. New York: Garland Publishing; 1994. p. 787-861.
32. Frankfurt O.S., Seckinger D., Sugarbaker E.V. Pleiotropic drug resistance and survival advantage in leukemic cells with diminished apoptotic response. Int. J. Cancer. 59:1994;217-224.
33. Smyth M.J., Krasoviskis E., Sutton V.R., Johnstone R.W. The drug efflux protein, P-glycoprotein, additionally protects drug-resistant tumor cells from multiple forms of caspase-dependent apoptosis. Proc. Natl. Acad. Sci. U.S.A. 95:1998;7024-7029.
34. Wang F.S., Kobayashi H., Liang K.W., Holland J.F., Ohnuma T. Retrovirus-mediated transfer of anti-MDR1 ribozymes fully restores chemosensitivity of P-glycoprotein-expressing human lymphoma cells. Hum. Gene Ther. 10:1999;1185-1195.
35. Chao Y., Chan W.K., Birkhofer M.J., Hu O.Y., Wang S.S., Huang Y.S., Liu M., Whang-Peng J., Chi K.H., Lui W.Y., Lee S.D. Phase II and pharmacokinetic study of paclitaxel therapy for unresectable hepatocellular carcinoma patients. Br. J. Cancer. 78:1998;34-39.
36. Katzenstein H.M., Krailo M.D., Malogolowkin M.H., Ortega J.A., Liu-Mares W., Douglass E.C., Feusner J.H., Reynolds M., Quinn J.J., Newman K., Finegold M.J., Haas J.E., Sensel M.G., Castleberry R.P., Bowman L.C. Hepatocellular carcinoma in children and adolescents: results from the Pediatric Oncology Group and the Children's Cancer Group intergroup study. J. Clin. Oncol. 20:2002;2789-2797.
37. Unger C. Current concepts of treatment in medical oncology: new anticancer drugs. J. Cancer Res. Clin. Oncol. 122:1996;189-198.